ELDN Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

IRVINE, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming Jefferies Healthcare Conference on Friday, June 9, 2023, at 9:00 a.m. ET.

To register in advance for the presentation webcast, sign up .

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at . 

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the company’s website at .

Follow Eledon Pharmaceuticals on social media: ;

Investor Contact:

Stephen Jasper

Gilmartin Group

(858) 525 2047

Source: Eledon Pharmaceuticals



EN
02/06/2023

Underlying

ELDNEledon Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eledon Pharmaceuticals Inc

 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Opera...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantati...

March 20, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healt...

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up . A webcast replay will be accessible following the live session on the Company’s website under ....

March 4, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component o...

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L) with potential to improve both safety and efficacy compared to standard of care immunosuppression regimens IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasd...

February 7, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Ca...

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT). To register in advance for the presentation webcast, sign up . A webcast replay will be ...

January 29, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provi...

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppress...

January 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch